Hospital
Vcu Health Tappahannock Hospital
Vcu Health Tappahannock Hospital was paid $20.60M by Medicaid between Jan 2018 and Dec 2024, across 206 billing codes. Its largest line is 99283, emergency room visit (moderate) — 21% of everything it billed.
33Billing provider infoVCU HEALTH TAPPAHANNOCK HOSPITAL
TAPPAHANNOCK, VA 22560
TAPPAHANNOCK, VA 22560
33aNPI1760580757assigned 09/21/2006
33bProvider typeRural Acute Care Hospital
28Total paid$20.60M
24GClaims450,951
24DCodes billed206
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Rural Acute Care Hospital providers in Virginia
Rank by total paid#4 of 6
Median peer was paid$20.60M
This provider vs. median1.0×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 43,447 | $1.07M | |
| 2019 | 64,991 | $1.86M | |
| 2020 | 57,999 | $1.91M | |
| 2021 | 69,932 | $2.17M | |
| 2022 | 72,523 | $3.60M | |
| 2023 | 78,035 | $6.00M | |
| 2024incomplete | 64,024 | $4.00M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 21% | 22,216 | 18,932 | $4.32M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 16% | 18,210 | 14,821 | $3.35M |
| 96361 | Intravenous infusion, hydration; each additional hour | 13% | 8,103 | 5,877 | $2.64M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 11% | 9,051 | 7,407 | $2.23M |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 4.9% | 4,026 | 3,426 | $1.00M |
| 70450 | Computed tomography, head or brain; without contrast material | 4.3% | 3,977 | 3,372 | $883K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 3.1% | 5,876 | 4,085 | $637K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 2.5% | 3,321 | 2,993 | $514K |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | 2.3% | 1,737 | 1,186 | $475K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 2.0% | 2,242 | 1,862 | $418K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | 1.7% | 1,476 | 1,356 | $347K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | 1.7% | 870 | 778 | $346K |
194 more codes
| G0378 | Hospital observation service, per hour | 1.7% | 1,262 | $342K |
| 71275 | Computed tomographic angiography, chest, with contrast material | 1.6% | 1,060 | $324K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 1.4% | 5,381 | $282K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | 1.1% | 2,031 | $230K |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | <1% | 1,148 | $166K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 2,381 | $158K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 1,935 | $119K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 8,672 | $115K |
| 97161 | <1% | 666 | $108K | |
| 80053 | Comprehensive metabolic panel | <1% | 22,775 | $107K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 2,092 | $102K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 2,420 | $93K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 6,862 | $88K |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | <1% | 6,565 | $66K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 6,915 | $65K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 561 | $65K |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 1,142 | $53K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 10,362 | $46K |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 1,417 | $46K |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 1,196 | $40K |
| 73630 | <1% | 1,580 | $38K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 555 | $37K |
| 71250 | <1% | 459 | $36K | |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 2,530 | $32K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 27,092 | $26K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 1,692 | $24K |
| 70498 | <1% | 96 | $23K | |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 320 | $23K |
| 73030 | <1% | 1,345 | $22K | |
| 84484 | <1% | 12,952 | $21K | |
| 73610 | <1% | 1,183 | $21K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 5,491 | $21K |
| 73130 | <1% | 875 | $19K | |
| 20610 | <1% | 235 | $19K | |
| 73564 | <1% | 562 | $18K | |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | <1% | 31 | $17K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 6,180 | $17K |
| 83880 | <1% | 2,394 | $16K | |
| 87040 | <1% | 2,728 | $16K | |
| 72100 | <1% | 681 | $15K | |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 15,477 | $15K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 2,062 | $15K |
| 93017 | <1% | 120 | $14K | |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 14 | $13K |
| 71045 | Radiologic examination, chest; single view | <1% | 8,522 | $13K |
| 83605 | <1% | 9,966 | $13K | |
| 73562 | <1% | 793 | $12K | |
| 96367 | <1% | 272 | $12K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 6,932 | $12K |
| 76642 | <1% | 102 | $12K | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 4,233 | $12K |
| 87081 | <1% | 4,944 | $10K | |
| 97162 | <1% | 53 | $10K | |
| 73502 | <1% | 630 | $9K | |
| 73110 | <1% | 410 | $9K | |
| 90715 | <1% | 256 | $8K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 5,560 | $7K |
| 85379 | <1% | 1,559 | $7K | |
| 80047 | <1% | 1,440 | $7K | |
| 80061 | Lipid panel | <1% | 1,091 | $6K |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 1,911 | $6K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 294 | $6K |
| 82948 | <1% | 2,383 | $6K | |
| 74018 | <1% | 254 | $6K | |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 322 | $5K |
| 81025 | <1% | 4,299 | $5K | |
| J3490 | Unclassified drugs | <1% | 7,288 | $5K |
| 87632 | <1% | 95 | $5K | |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 97 | $5K |
| 83735 | <1% | 9,791 | $5K | |
| 86756 | <1% | 339 | $5K | |
| 93971 | <1% | 63 | $5K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 883 | $4K |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 1,125 | $4K |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 7,132 | $4K |
| 82248 | <1% | 1,078 | $3K | |
| 85027 | <1% | 874 | $3K | |
| 84466 | <1% | 243 | $3K | |
| 80143 | <1% | 543 | $3K | |
| 82728 | <1% | 403 | $3K | |
| 96376 | <1% | 3,106 | $3K | |
| 81001 | <1% | 11,910 | $3K | |
| 87581 | <1% | 97 | $3K | |
| 87486 | <1% | 97 | $3K | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 356 | $2K |
| G0472 | Hepatitis c antibody screening, for individual at high risk and other covered indication(s) | <1% | 58 | $2K |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 6,997 | $2K |
| A9577 | Injection, gadobenate dimeglumine (multihance), per ml | <1% | 166 | $2K |
| 73140 | <1% | 115 | $2K | |
| 84702 | <1% | 1,383 | $2K | |
| 76830 | Ultrasound, transvaginal | <1% | 14 | $2K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 6,086 | $2K |
| 73560 | <1% | 154 | $2K | |
| 85610 | <1% | 2,247 | $2K | |
| 83540 | <1% | 326 | $2K | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 325 | $1K |
| 82607 | <1% | 143 | $1K | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 2,568 | $1K |
| 80179 | <1% | 499 | $1K | |
| 83690 | <1% | 5,954 | $1K | |
| 84439 | <1% | 172 | $1K | |
| 86140 | <1% | 346 | $1K | |
| 83655 | <1% | 44 | $1K | |
| J2704 | Injection, propofol, 10 mg | <1% | 4,176 | $973.54 |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 1,853 | $970.85 |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 514 | $968.22 |
| A9585 | Injection, gadobutrol, 0.1 ml | <1% | 29 | $924.12 |
| 81003 | <1% | 3,328 | $892.48 | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 1,855 | $866.67 |
| 87077 | <1% | 2,290 | $845.18 | |
| 82553 | <1% | 204 | $834.63 | |
| 77062 | <1% | 31 | $813.02 | |
| 76942 | <1% | 19 | $803.11 | |
| J2550 | Injection, promethazine hcl, up to 50 mg | <1% | 478 | $764.65 |
| 82947 | <1% | 3,104 | $678.97 | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 4,563 | $662.94 |
| 87430 | <1% | 2,431 | $524.22 | |
| 82077 | <1% | 701 | $501.38 | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 1,920 | $470.05 |
| 86900 | <1% | 465 | $431.56 | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 965 | $418.49 |
| 72110 | <1% | 12 | $411.70 | |
| 80320 | <1% | 378 | $366.44 | |
| Q9963 | High osmolar contrast material, 350-399 mg/ml iodine concentration, per ml | <1% | 160 | $365.47 |
| J2274 | Injection, morphine sulfate, preservative-free for epidural or intrathecal use, 10 mg | <1% | 54 | $344.37 |
| 87147 | <1% | 223 | $344.24 | |
| 84100 | <1% | 400 | $339.63 | |
| 82550 | <1% | 521 | $315.65 | |
| 84703 | <1% | 948 | $291.59 | |
| 80076 | <1% | 92 | $285.23 | |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 1,205 | $271.55 |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 3,130 | $236.15 |
| J1642 | Injection, heparin sodium, (heparin lock flush), per 10 units | <1% | 1,118 | $233.86 |
| 74022 | <1% | 41 | $229.68 | |
| 82565 | <1% | 344 | $228.92 | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 1,737 | $219.94 |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 720 | $219.78 |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 315 | $218.60 |
| 86901 | <1% | 465 | $210.32 | |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 697 | $204.45 |
| 87186 | <1% | 1,211 | $180.40 | |
| 72070 | <1% | 13 | $176.66 | |
| 85730 | <1% | 798 | $168.45 | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 55 | $165.75 |
| A9150 | Non-prescription drugs | <1% | 7,682 | $153.88 |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 30 | $152.23 |
| 82746 | <1% | 29 | $151.59 | |
| 73080 | <1% | 13 | $149.08 | |
| J1030 | Injection, methylprednisolone acetate, 40 mg | <1% | 466 | $148.40 |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | <1% | 678 | $144.14 |
| 85014 | <1% | 1,455 | $133.72 | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 1,705 | $126.81 |
| 87070 | <1% | 12 | $123.38 | |
| 82150 | <1% | 355 | $117.65 | |
| 86850 | <1% | 191 | $117.37 | |
| G0279 | Diagnostic digital breast tomosynthesis, unilateral or bilateral (list separately in addition to 77065 or 77066) | <1% | 14 | $115.79 |
| J7620 | Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, fda-approved final product, non-compounded, administered through dme | <1% | 228 | $104.64 |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 451 | $102.06 |
| 86885 | <1% | 75 | $100.00 | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 382 | $96.80 |
| 85652 | <1% | 34 | $92.73 | |
| 87184 | <1% | 251 | $84.61 | |
| 36592 | <1% | 278 | $82.19 | |
| 82805 | <1% | 40 | $64.28 | |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 1,669 | $56.58 |
| J2060 | Injection, lorazepam, 2 mg | <1% | 481 | $53.47 |
| A6402 | Gauze, non-impregnated, sterile, pad size 16 sq. in. or less, without adhesive border, each dressing | <1% | 158 | $37.69 |
| 82803 | <1% | 218 | $33.99 | |
| 87205 | <1% | 13 | $33.08 | |
| 82043 | <1% | 12 | $30.78 | |
| 87210 | <1% | 79 | $26.27 | |
| 81002 | <1% | 390 | $24.81 | |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 350 | $24.11 |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 248 | $11.18 |
| J1815 | Injection, insulin, per 5 units | <1% | 41 | $3.30 |
| J3480 | Injection, potassium chloride, per 2 meq | <1% | 44 | $3.12 |
| J1630 | Injection, haloperidol, up to 5 mg | <1% | 47 | $2.38 |
| J7510 | Prednisolone oral, per 5 mg | <1% | 49 | $2.21 |
| J1940 | Injection, furosemide, up to 20 mg | <1% | 24 | $1.70 |
| J0780 | Injection, prochlorperazine, up to 10 mg | <1% | 32 | $1.44 |
| A6222 | Gauze, impregnated with other than water, normal saline, or hydrogel, sterile, pad size 16 sq. in. or less, without adhesive border, each dressing | <1% | 63 | $0.21 |
| J2543 | Injection, piperacillin sodium/tazobactam sodium, 1 gram/0.125 grams (1.125 grams) | 0% | 118 | $0.00 |
| A9270 | Non-covered item or service | 0% | 4,402 | $0.00 |
| J2003 | Injection, lidocaine hydrochloride, 1 mg | 0% | 73 | $0.00 |
| 94760 | 0% | 111 | $0.00 | |
| 96368 | 0% | 12 | $0.00 | |
| J2785 | Injection, regadenoson, 0.1 mg | 0% | 16 | $0.00 |
| A9500 | Technetium tc-99m sestamibi, diagnostic, per study dose | 0% | 17 | $0.00 |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | 0% | 125 | $0.00 |
| 73590 | 0% | 18 | $0.00 | |
| C9113 | Injection, pantoprazole sodium, per vial | 0% | 34 | $0.00 |
| J2272 | Injection, morphine sulfate (fresenius kabi), not therapeutically equivalent to j2270, up to 10 mg | 0% | 18 | $0.00 |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | 0% | 195 | $0.00 |
| J1171 | Injection, hydromorphone, 0.1 mg | 0% | 17 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialHARLAN, ELIZABETH (REVENUE CYCLE DIRECTOR)
| Provider | Location | Paid |
|---|---|---|
| Virginia Commonwealth University Health System Authority | Richmond, VA | $658.49M |
| Community Memorial Hospital | South Hill, VA | $35.67M |
| Virginia Commonwealth University Health System Authority | Richmond, VA | $0.00 |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.